Dechra Veterinary Products is pleased to announce its exclusive marketing, sales, and distribution agreement with I-MED Pharma, the Canadian leader in dry eye management, for three innovative veterinary hyaluronic acid (HA) ophthalmic products.
Dechra has licensed the North American, long-term, veterinary rights for the following three products:
0.20% viscoadaptive HA suspension with osmoprotectants and bioprotectants
0.40% viscoadaptive HA ointment
0.18% viscoadaptive HA solution
Dechra will be launching these new products under the brand name OphtHAvet™ and will continue to collaborate with I-MED’s Chief Scientific Officer and founder, Dr. Ilan Hofmann regarding HA research and new product development. With over 30 years of experience specializing in dry eye diagnosis and management, Dr. Hofmann is recognized as a leader in ocular surface disease and for developing the highest quality and efficacious HA ophthalmic products.
The OphtHAvet portfolio is expected to launch later this year and will be the latest addition to Dechra’s veterinary ophthalmic portfolio, which currently includes Isathal Eye gel, Lubrithal Eye gel, and CleanOcular.
Philipp Binder, President of I-MED Pharma stated, “This partnership with Dechra allows us to pursue our vision of making our industry-leading technology accessible to as many patients as possible. The collaboration in product development will further push the boundaries of science and ensure we can continue to bring the most cutting-edge products to market.”
Mike Eldred, President of North American Operations for Dechra, commented: “We are pleased to have partnered with I-MED Pharma and we look forward to launching these innovative HA veterinary ophthalmics. With the addition of these innovative products, Dechra will be well-positioned to provide veterinarians with a wide range of veterinary-approved ophthalmics to help treat and resolve their everyday challenges.”
Dechra Veterinary Products
National Sales Manager
Dechra Veterinary Products
About I-MED Pharma
I-MED Pharma Inc. is a privately held Canadian company, headquartered in Montreal, Quebec. As a research-based firm with the vision to be the most important dry eye and ocular surface disease company in the world, I-MED Pharma provides innovative OSD solutions to the global optometry and ophthalmology community. Through the years, I-MED Pharma has continuously invested heavily in R&D and has created unique and effective products for the management of dry eye disease. A pioneer in the field of artificial tears and ocular hygiene cleansers, I-MED Pharma’s signature product lines include I-DROP® and I-LID ’N LASH®, which are sold around the world.
I-MED Pharma offers a complete range of ocular surface disorder products, including diagnostic tools, artificial tears, dry eye ointment, ocular hygiene cleansers, punctum plugs, nutritional supplements, therapeutic accessories, as well as the E-Eye IRPL®, a long-lasting solution designed specifically for the treatment of dry eyes due to Meibomian Gland Dysfunction.
For more information, please email firstname.lastname@example.org or visit www.imedpharma.com